Chase Sun Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 80.7629 million yuan, a decrease of 52.03%

Chase Sun Pharmaceuticals released its Q3 2025 report, with a revenue of 4.149 billion yuan for the first three quarters, a year-on-year decrease of 6.59%. The net profit attributable to the parent company was 80.7629 million yuan, a year-on-year decline of 52.03%. The net profit after deducting non-recurring gains and losses was 88.7048 million yuan, a year-on-year decrease of 43.81%. The basic earnings per share were 0.03 yuan

Chase Sun Pharmaceuticals released its performance for the first half of the year, with a net profit attributable to the parent company of 78.63 million yuan, a decrease of 46.95%

According to the Zhitong Finance APP, Chase Sun released its semi-annual report for 2025, showing an operating income of 2.795 billion yuan, a year-on-year decrease of 6.72%. The net profit attributable to shareholders of the listed company was 78.63 million yuan, a year-on-year decrease of 46.95%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 69.1796 million yuan, a year-on-year decrease of 49.53%. The basic earnings per share were 0.03 yuan

The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising

Chase Sun Pharmaceuticals released its first-quarter performance, with a net profit attributable to the parent company of 60.3297 million yuan, an increase of 3.80%

According to the Zhitong Finance APP, Chase Sun released its first-quarter report for 2025, with operating revenue of 1.393 billion yuan, a year-on-year decrease of 4.82%. The net profit attributable to shareholders of the listed company was 60.3297 million yuan, a year-on-year increase of 3.80%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 54.8592 million yuan, a year-on-year increase of 1.26%. The basic earnings per share were 0.02 yuan

Hubei Chenmei Traditional Chinese Medicine signed agreements with multiple parties to jointly promote the high-quality development of the entire industrial chain of Dabieshan authentic medicinal materials

Recently, Chase Sun's subsidiary Hubei Chenmei Traditional Chinese Medicine Co., Ltd. signed a cooperation agreement with the Agricultural Science Institute of Huanggang City, Hubei Province, Hubei University of Traditional Chinese Medicine, and Hubei Provincial Hospital of Traditional Chinese Medicine for the "Research Project on the Integration of Ecological Planting Technology and High-Value Utilization of Local Medicinal Materials in the Dabie Mountains." All parties will cooperate on related content to achieve collaborative innovation in production, education, research, and application